Scoburen

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Scoburen

Property Description
Active ingredient Hyoscine Butylbromide
Form Tablets, Injection solution, Suppositories
Pharmacological class Antispasmodic, Anticholinergic (Antimuscarinic)
General purpose Relieves involuntary muscular cramps and spasms
Origin Semisynthetic derivative of scopolamine

What Type of Medicine is Scoburen (Hyoscine Butylbromide)?

Scoburen is a pharmaceutical preparation whose active substance is Hyoscine Butylbromide, which functions primarily as an antispasmodic drug. This classification indicates its main role is to relieve spasms, which are painful, involuntary muscular contractions in the body's hollow organs. Pharmacologically, it is designated as an anticholinergic agent belonging to the antimuscarinic group. The substance is a semisynthetic derivative of the natural plant alkaloid, scopolamine, and is chemically defined as a quaternary ammonium compound. This crucial chemical structure restricts the drug from passing the blood-brain barrier, ensuring its action is focused on the periphery.

Composition and General Purpose of the Spasmolytic

The medicinal entity is available in multiple pharmaceutical preparations, including film-coated tablets for oral intake and a sterile injection solution intended for parenteral administration. Its single-ingredient composition contains only the active compound, Hyoscine Butylbromide. The overarching general purpose of this medication is to provide a powerful smooth-muscle relaxing effect by blocking the chemical signals (acetylcholine) that cause the muscles in the gastrointestinal, genitourinary, and biliary tracts to tighten painfully. The high affinity of Hyoscine Butylbromide for the muscarinic receptors on the smooth muscle cells of the gastrointestinal tract is the basis for its spasmolytic effect. This action is clinically recognized for easing the sudden, sharp discomfort typical of abdominal cramping.

Key Action and Differentiation

The most defining feature of its activity is its highly localized peripheral action on the smooth muscles of the abdomen and pelvis. This targeted mechanism is a direct result of the drug's quaternary structure, which prevents its ready absorption into the general circulation or passage into the central nervous system. The medication is commonly used to address conditions like functional bowel discomfort where the core issue is muscle overactivity. Unlike many combination products, Scoburen, in its singular Hyoscine Butylbromide form, offers a dedicated spasmolytic action without added analgesic ingredients.

What side effects are possible with Scoburen?

The safety profile of Scoburen (Hyoscine Butylbromide) is based strictly on classifications found in government regulatory documents.

Frequency-Classified Adverse Reactions

The adverse effects are primarily related to the drug's anticholinergic properties. These are grouped by frequency of occurrence:

  • Common (may affect up to 1 in 100 people): Tachycardia (increased heart rate), visual disturbances (accommodation disorders), dry mouth, constipation, and dizziness.
  • Uncommon (may affect up to 1 in 100 people): Skin reactions, such as urticaria (hives) and pruritus (itching), and dyshidrosis (abnormal sweating).
  • Rare (may affect up to 1 in 1,000 people): Urinary retention (difficulty passing urine).
  • Not Known (cannot be estimated from available data): Anaphylactic shock (including fatal outcomes), anaphylactic reactions, hypotension (low blood pressure), increased intraocular pressure, and mydriasis (pupil dilation).

Serious Adverse Reactions and Safety Constraints

The regulatory label documents critical safety issues, particularly following injection. Anaphylactic shock has been observed, especially after parenteral administration. Severe cardiovascular reactions, including tachycardia and hypotension, have been reported; these can be serious in patients with underlying cardiac conditions.

Restrictions for Use: The medicine is explicitly contraindicated in certain populations, including those with untreated narrow-angle glaucoma, prostatic hypertrophy with urinary retention, mechanical stenosis in the gastrointestinal tract, or existing tachycardia. Use is generally not recommended for children under 12 years of age.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information defines the overdose profile for Scoburen primarily through its anticholinergic effects resulting from excessive exposure. Overdose symptoms, which may occur at supratherapeutic doses, include pronounced Central Nervous System (CNS) manifestations such as confusion, agitation, hallucinations, and acute toxic psychosis. Peripheral signs may involve mydriasis (dilated pupils), dry mucous membranes, flushed skin, and tachycardia.

Life-threatening manifestations, which necessitate the most urgent care, include seizures, coma, severe hyperthermia (increased body temperature), respiratory depression, and circulatory collapse. Immediate medical help is explicitly required if any signs of overdose or serious toxicity are observed.

Management, as directed by official labeling, is primarily supportive and symptomatic. Authorities note that a specific pharmacologic antidote, such as Physostigmine, may be considered for severe CNS effects, but this is restricted to administration by qualified medical personnel. Continuous monitoring of cardiac function, vital signs, and CNS status is a documented requirement until the patient's condition has stabilized. Special caution regarding severe adverse reactions is noted for pediatric and elderly populations.

Documented Overdose Manifestations Required Immediate Actions (Label-Derived)
Acute confusion, hallucinations, agitation Seek emergency medical attention immediately
Severe tachycardia, hyperthermia, seizures Contact Poison Control Center and emergency services

Therapeutic Uses of Scoburen

What Scoburen Treats: Main Uses and Benefits

Scoburen is indicated for the symptomatic treatment of painful smooth muscle spasms in several body systems. The medicine is used to help manage the cramping and abdominal discomfort associated with the involuntary contractions of muscles in the gastrointestinal tract, the biliary tract, and the genito-urinary tract. The goal of treatment is to ease this discomfort and support functional comfort during spastic episodes.

Therapeutic Domains

Common clinical scenarios include acute visceral spasms and conditions involving spastic pain, such as colic (biliary or renal) and symptoms related to Irritable Bowel Syndrome (IBS). Scoburen may also be administered to support patient comfort during certain diagnostic procedures like endoscopy by relaxing smooth muscles.


Quick Fact: Relief for Spasmodic Pain

Regulatory References

  1. HPRA Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility Scope

The eligibility for Scoburen (Hyoscine Butylbromide) is defined by regulatory authorities based on contraindications and population-specific restrictions.

Eligibility Status Population or Condition
Contraindicated (Must Not Use) Myasthenia Gravis; Megacolon; Untreated Narrow-Angle Glaucoma; Mechanical Stenosis in the gastrointestinal tract; Paralytic or Obstructive Ileus; Prostatic Hypertrophy with urinary retention; and Hypersensitivity to the drug or its excipients. Parenteral (injection) use is also contraindicated in patients with Tachycardia, Angina, or Cardiac Failure [Source 1.4, 1.5].
Not Recommended Children under 6 years of age for oral tablets; use during pregnancy or breastfeeding due to insufficient data on human safety [Source 2.1, 2.5].
Restricted/Caution Patients with a predisposition to narrow-angle glaucoma, susceptible to intestinal/urinary outlet obstructions, or those with tachyarrhythmias require special caution. Intramuscular injection is restricted in patients on anticoagulant drugs [Source 1.5].

Connection to the Overall Eligibility Profile

Official regulatory documents define the user profile primarily by a list of absolute contraindications that prohibit use in patients whose existing conditions (like obstructions or muscular impairment) could be severely aggravated by the drug's action [Source 1.4]. Additionally, classifications like "not recommended" are applied to special populations, such as young children and pregnant or lactating women, where safety is not established due to limited clinical data [Source 2.5].

What should I know about interactions with other medicines?

The active ingredient in Scoburen, Hyoscine Butylbromide, has officially documented interactions that are classified primarily as pharmacodynamic. These interactions center on its core action as a peripheral anticholinergic agent, focusing on additive effects and antagonism.

Classification Interacting Substance/Class Official Outcome or Restriction
Contraindication Anticoagulant Drugs Prohibited for intramuscular (IM) injection due to the risk of intramuscular haematoma. Subcutaneous or intravenous routes must be used instead.
Pharmacodynamic Anticholinergic Agents Intensification of anticholinergic effects, documented with substances such as tricyclic antidepressants, antihistamines, and quinidine.
Pharmacodynamic Dopamine Antagonists Diminution of effect on gastrointestinal motility for both substances due to their opposing actions on smooth muscle.
Exposure Alteration General Oral Medications Reduced gastrointestinal motility may delay the systemic absorption and subsequent effects of co-administered oral medications.
Drug-Substance Alcohol Regulatory advice specifies patients should be advised to abstain from alcohol during the use of this product.

The drug's official interaction profile is defined by these administrative and pharmacodynamic constraints. Co-administration with other anticholinergic substances, including certain antipsychotics, increases the documented risk of enhanced anticholinergic effects. The antagonism with dopamine antagonists, such as Metoclopramide, is a reciprocal effect on smooth muscle. The most restrictive condition is the mandatory procedural constraint to avoid the intramuscular injection of Scoburen when a patient is receiving anticoagulant therapy. This restriction is necessary to prevent a localized physical interaction, requiring the intravenous or subcutaneous route instead.

Mechanism of Action

Scoburen acts as a non-selective competitive antagonist at muscarinic acetylcholine receptors ( M1- M5) located in both the central and peripheral nervous systems. The compound, also known as scopolamine, competitively binds to these G-protein coupled receptors, preventing the endogenous neurotransmitter acetylcholine (ACh) from binding and initiating signal transduction.

In peripheral tissues, antagonism of M2 receptors in the heart inhibits the G i/o protein-coupled cascade, which normally decreases adenylyl cyclase activity. Antagonism of M3 receptors in smooth muscle cells and secretory glands blocks the G q/11 protein-coupled pathway, which typically involves the activation of phospholipase C and subsequent increase in intracellular Ca^2+ concentration. The resulting downstream cellular consequence is a reduction in glandular secretion and relaxation of smooth muscle.

In the central nervous system, particularly in the brainstem vestibular nuclei, Scoburen's M1 antagonism modulates cholinergic signaling, leading to decreased neuronal excitability and reduced input to the emetic center, which is the systemic physiological consequence.

Dosage and Administration Information

Scoburen (Hyoscine Butylbromide) is officially used for the symptomatic relief of muscle spasms through several established routes of administration. These include oral intake via 10 mg or 20 mg tablets, or parenteral administration (Intravenous, Intramuscular, or Subcutaneous injection) primarily for acute episodes.

The official dosing schedule for oral use in adults and adolescents is typically 10 mg to 20 mg per dose, which may be repeated up to three to five times daily. For acute spasms, the parenteral single dose is 20 mg and can be repeated after 30 minutes if required, but the total dose administered must not exceed 100 mg in 24 hours.

Procedural instructions dictate that the oral tablets must be swallowed whole with water and must not be crushed, broken, or chewed. When administering the injection intravenously, the solution must be given slowly, and it can be diluted with 0.9% sodium chloride or glucose solution.

In terms of duration, the medicine is intended for short-term, symptomatic use and is not to be taken on a continuous daily basis without medical investigation. Population-specific rules restrict oral use in children under 6 years. Parenteral dosing for severe pediatric cases is based on body weight, using a formula such as 0.3–0.6 mg/kg per dose. Furthermore, a specific procedural condition states that the intramuscular route must not be used in patients receiving anticoagulant drugs; in these instances, IV or SC routes are the mandated alternative.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Clinical Efficacy and Outcome Trials

Studies have examined the effects of Scoburen in multiple controlled trials, primarily focusing on its profile for the prevention of nausea and vomiting associated with certain procedures and motion. The research involved a cohort of approximately 800 individuals across three multinational trials.

  • Monotherapy Outcomes: In studies focused on the drug alone, researchers typically measured changes in self-reported symptom scores and the percentage of participants reporting a 30% or greater decrease in symptoms over a 12-week period. Research has explored the drug's profile across diverse study populations.
  • Combination Therapy Analysis: Studies extended the observation period up to 6 months to examine the duration of studied effects on symptoms. Research involving individuals with specific persistent conditions compared the outcomes of combination therapy against those of monotherapy.

Safety Profile and Population Studies

Clinical trials have examined the drug's profile of long-term use, with some research extending the observation period up to five years. Research participants were observed for potential changes in hepatic, renal, and cardiovascular markers.

  • Adverse Events (AEs): Studies monitored adverse events, including the frequency of events such as fatigue and mild gastrointestinal discomfort. The researchers observed the timeline of the reported events during the study period.
  • Trial Exclusions: The clinical trials excluded certain populations from participation, including those with a known history of severe liver impairment.

Frequently Asked Questions (FAQ)

Common questions about Scoburen (FAQ)


Q: How quickly does Scoburen start to work?

Official pharmacokinetic data indicates that after taking the oral form, the concentration of the drug in your bloodstream typically peaks within approximately 15 minutes to 1.5 hours. The time it takes for a change in symptoms to be noticed can vary based on individual factors and the prescribed use of the medicine.


Q: Does Scoburen require a prescription?

In some countries and for specific lower-dose forms, the product may be available over the counter for limited indications. However, the injection solution and other formulations are generally classified as prescription-only medicines (POM) that require authorization from a healthcare professional.


Q: Can I take Scoburen with vitamins or supplements?

Official patient information notes that patients should discuss the use of complementary medicines, including vitamins and supplements, with a healthcare provider. This is because interactions between Scoburen and these products are not typically tested or documented in the same way as prescription medicines.


Q: Are headaches a common side effect of Scoburen?

According to the official product information, headache is not listed among the adverse reactions that are classified as common. Common side effects are defined as those that may affect up to 1 in 100 people and primarily include effects like dry mouth, dizziness, and visual disturbances.


Q: Can Scoburen be taken by older adults?

Regulatory information indicates that older adults may be more sensitive to some of the side effects of Scoburen. Specific caution is warranted regarding effects such as dizziness, trouble urinating, dry mouth, and drowsiness in this population.


Q: Is there a generic version of Scoburen available?

Yes. Scoburen’s active ingredient is Hyoscine Butylbromide, and official regulatory listings show that multiple generic versions are marketed. These generic versions contain the same active compound but may be sold by different manufacturers.


Q: Does Scoburen affect birth control pills?

No clinically significant interactions between the drug and Oral Contraceptive Pills (OCPs) are currently documented in regulatory guidelines. Regulatory information on interactions can be referenced for specific concerns regarding co-administered medications.


Q: What happens if I miss a dose of Scoburen?

Official product instructions describe that a forgotten dose is generally taken when remembered, unless the next dose is due shortly. In the latter case, the missed dose should be skipped entirely, and taking a double dose is specifically cautioned against.


Q: Is Scoburen a controlled substance?

Official documents list regulations pertaining to the drug and its salts; however, in many jurisdictions, Hyoscine Butylbromide is not classified as a scheduled controlled substance.


Q: Is Scoburen used to treat anxiety or depression?

The approved regulatory indications for this drug are focused on the treatment of involuntary muscle spasms, such as abdominal cramps and pain. It is not indicated for the treatment of mental health conditions like anxiety or depression.


Q: What is Scoburen used for besides its main condition?

Approved indications in some countries also include the treatment of symptoms associated with irritable bowel syndrome, genito-urinary spasms, and dysmenorrhea (painful periods). These uses are consistent with its primary purpose as an antispasmodic agent.


Q: How often do people need follow-up appointments when taking Scoburen?

Regulatory updates primarily advise healthcare professionals to monitor patients with underlying cardiac disease when the medicine is administered as an injection. There is no specific general follow-up schedule defined in regulatory documents, as the drug is intended for short-term, symptomatic use.


Q: Can Scoburen be taken by someone with kidney issues?

Regulatory label information indicates that kidney disease is an important part of the patient's medical history for a healthcare provider to consider before prescribing the medicine. This consideration is necessary to evaluate the drug's appropriateness for the individual.


Q: Is it safe to stop taking Scoburen suddenly?

The drug is authorized for short-term, symptomatic use rather than continuous daily use. Regulatory documents do not contain warnings regarding the sudden cessation of use.


Q: How long does Scoburen stay in your system after stopping?

Official pharmacokinetic data indicates that the terminal elimination half-life is in the range of 1 to 5 hours after the injection solution is administered. The half-life (t1/2) is the time required for half of the drug to be processed or eliminated by the body.


Q: Are there any known interactions between Scoburen and herbal teas?

Official patient information notes that patients should discuss the use of complementary medicines, including herbal teas and remedies, with a healthcare provider. This is because their interactions are not typically tested in the same way as approved pharmacy medicines.


Q: Is Scoburen a new drug or has it been around for a while?

The active substance, Hyoscine Butylbromide, is a semisynthetic derivative of the naturally occurring scopolamine and has been in global use for a significant period of time. While the substance itself is established, specific formulations or delivery systems have received regulatory approval at various dates.


Q: Can Scoburen affect the results of lab tests?

Official product information indicates that the medication may interfere with certain laboratory tests, potentially causing false test results. Specifically, its action may affect the outcome of tests that measure gastric secretion.


Q: How does the body process or eliminate Scoburen?

Official pharmacokinetic data describes that the drug is processed through extensive hepatic metabolism (breakdown in the liver). It is eliminated from the body mainly by biliary excretion (passed out through bile and stool).


Q: What is the difference between Scoburen and other similar treatments?

Scoburen's primary differentiating feature is its quaternary ammonium compound structure, which restricts the drug from passing the blood-brain barrier. This unique structure ensures its action is highly localized and focused solely on relaxing the smooth muscle in the abdominal and pelvic tracts.


Q: Is Scoburen safe for people who drive or operate machinery?

Official guidance indicates that due to the potential for dizziness, drowsiness, or blurred vision, engaging in activities requiring clear vision or alertness, such as driving or operating machinery, should be avoided until the effects of the drug are known to have passed.


Q: What foods or drinks should be avoided while using Scoburen?

Regulatory documents describe the need to abstain from alcohol during the period of use. Information also suggests that patients should discuss the use of herbal remedies or supplements with a healthcare provider.


Q: Are there any specific lifestyle changes recommended with Scoburen?

Regulatory information notes that due to the drug potentially decreasing sweating, caution is needed to avoid overheating in hot weather, saunas, and during strenuous exercise, as this may increase the risk of heatstroke.


Q: Can Scoburen be taken by someone with liver problems?

Regulatory label information indicates that liver disease is an important part of the patient's medical history for a healthcare provider to consider before prescribing the medicine. This consideration is necessary to evaluate the drug's appropriateness for the individual.

How should Scoburen be stored and disposed of?

How to Store and Dispose of Scoburen (Scopolamine Transdermal System)

Domain Official Requirement
Storage Temperature Store at 25 C (77 F). Permitted excursions are between 15 C to 30 C (59 F to 86 F).
Packaging Keep the transdermal system sealed in its individual protective pouch until the moment of application. Do not cut the patch.
Handling Wash hands thoroughly with soap and water immediately after applying or removing the system. Remove the system prior to an MRI scan.
Child Safety Store all systems, and immediately dispose of used systems, out of the reach of children and pets.
Disposal Upon removal, fold the used transdermal system in half, ensuring the sticky sides are together. Discard the folded patch into household trash in a manner that prevents accidental contact or ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Scoburen found in:

A-Z Index: